CONSTANCE GAWUM: Open Payments
NPI 1356609754 · UPPER MARLBORO, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,480 in 72 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $156 · 2025 $1,480
Food & beverage: $1,480
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $404 |
| Alkermes, Inc. | 15 | $283 |
| Otsuka America Pharmaceutical, Inc. | 11 | $216 |
| ABBVIE INC. | 9 | $163 |
| Teva Pharmaceuticals USA, Inc. | 6 | $141 |
| E.R. Squibb & Sons, L.L.C. | 5 | $111 |
| Janssen Pharmaceuticals, Inc | 3 | $102 |
| Vanda Pharmaceuticals Inc. | 1 | $40 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
Products named: CAPLYTA, ARISTADA, VRAYLAR, LYBALVI, COBENFY, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
